http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 14:52:56 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Corporate+News/Azenta+names+board+member+as+interim+CEO+after+Marotta+resigns/26964448.html <p>Azenta, Inc. (Nasdaq: AZTA) announced that John Marotta has resigned as president, CEO, and director, and that board member Dr. Martin Madaus has been appointed interim president and CEO, according to a company press release dated Aug. 24, 2026.</p><p>Dr. Madaus has served on the Azenta board since 2024 and is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG). He has previously held CEO roles at Millipore Corporation, Ortho-Clinical Diagnostics, and Roche Diagnostics North America.</p><p>The company said it has retained search firm Heidrick & Struggles to conduct a permanent CEO search.</p><p>Azenta reaffirmed its previously issued fourth quarter fiscal http://www.streetinsider.com/Corporate+News/Azenta+names+board+member+as+interim+CEO+after+Marotta+resigns/26964448.html Mon, 24 Aug 2026 08:01:03 -0400 AZTA CG HAE ROG http://www.streetinsider.com/Corporate+News/Azenta+names+board+member+as+interim+CEO+after+Marotta+resigns/26964448.html <p>Azenta, Inc. (Nasdaq: AZTA) announced that John Marotta has resigned as president, CEO, and director, and that board member Dr. Martin Madaus has been appointed interim president and CEO, according to a company press release dated Aug. 24, 2026.</p><p>Dr. Madaus has served on the Azenta board since 2024 and is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG). He has previously held CEO roles at Millipore Corporation, Ortho-Clinical Diagnostics, and Roche Diagnostics North America.</p><p>The company said it has retained search firm Heidrick & Struggles to conduct a permanent CEO search.</p><p>Azenta reaffirmed its previously issued fourth quarter fiscal http://www.streetinsider.com/Corporate+News/Azenta+names+board+member+as+interim+CEO+after+Marotta+resigns/26964448.html Mon, 24 Aug 2026 08:01:03 -0400 AZTA CG HAE ROG http://www.streetinsider.com/Corporate+News/Azenta+names+board+member+as+interim+CEO+after+Marotta+resigns/26964448.html <p>Azenta, Inc. (Nasdaq: AZTA) announced that John Marotta has resigned as president, CEO, and director, and that board member Dr. Martin Madaus has been appointed interim president and CEO, according to a company press release dated Aug. 24, 2026.</p><p>Dr. Madaus has served on the Azenta board since 2024 and is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG). He has previously held CEO roles at Millipore Corporation, Ortho-Clinical Diagnostics, and Roche Diagnostics North America.</p><p>The company said it has retained search firm Heidrick & Struggles to conduct a permanent CEO search.</p><p>Azenta reaffirmed its previously issued fourth quarter fiscal http://www.streetinsider.com/Corporate+News/Azenta+names+board+member+as+interim+CEO+after+Marotta+resigns/26964448.html Mon, 24 Aug 2026 08:01:03 -0400 AZTA CG HAE ROG http://www.streetinsider.com/Corporate+News/Azenta+names+board+member+as+interim+CEO+after+Marotta+resigns/26964448.html <p>Azenta, Inc. (Nasdaq: AZTA) announced that John Marotta has resigned as president, CEO, and director, and that board member Dr. Martin Madaus has been appointed interim president and CEO, according to a company press release dated Aug. 24, 2026.</p><p>Dr. Madaus has served on the Azenta board since 2024 and is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG). He has previously held CEO roles at Millipore Corporation, Ortho-Clinical Diagnostics, and Roche Diagnostics North America.</p><p>The company said it has retained search firm Heidrick & Struggles to conduct a permanent CEO search.</p><p>Azenta reaffirmed its previously issued fourth quarter fiscal http://www.streetinsider.com/Corporate+News/Azenta+names+board+member+as+interim+CEO+after+Marotta+resigns/26964448.html Mon, 24 Aug 2026 08:01:03 -0400 AZTA CG HAE ROG